Bank of New York Mellon’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-204,023
Closed -$91.4K 4487
2022
Q4
$91.4K Sell
204,023
-1,593
-0.8% -$659 ﹤0.01% 4132
2022
Q3
$100K Hold
205,616
﹤0.01% 4197
2022
Q2
$103K Sell
205,616
-1,403
-0.7% -$679 ﹤0.01% 4219
2022
Q1
$126K Buy
+207,019
New +$109K ﹤0.01% 4358
2021
Q2
Sell
-11,090
Closed -$69K 4505
2021
Q1
$69K Buy
+11,090
New +$98.2K ﹤0.01% 4212

Other funds holding MTCR

Bank of New York Mellon's MTCR Position: Q1 2023 in Review

Bank of New York Mellon sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 204,023 shares — an estimated $91.4K sold.

Bank of New York Mellon first reported a position in MTCR in Q1 2021 and held it in 5 quarters. The position peaked at $126K in Q1 2022. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Bank of New York Mellon reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 204,023 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $91.4K.
  • Bank of New York Mellon first reported a position in Metacrine, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Bank of New York Mellon's Metacrine, Inc. Common Stock position peaked at $126K in Q1 2022.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.